**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**ESPS manuscript NO: 2503**

**Columns: REVIEW**

**Management of potentially resectable colorectal cancer liver metastases**

Meriggi F *et al.* Management of potentially resectable colorectal cancer liver metastases

Fausto Meriggi, Paola Bertocchi, Alberto Zaniboni

**Fausto Meriggi, Paola Bertocchi, Alberto Zaniboni,** Oncology Department, Istituto Ospedaliero Fondazione Poliambulanza, 25124 Brescia, Italy

**Author contributions:** Meriggi F, Bertocchi P and Zaniboni A contribuited equally to this paper.

**Correspondence to: Alberto Zaniboni, MD,** Oncology Department, Istituto Ospedaliero Fondazione Poliambulanza, via Bissolati 57, 25124 Brescia, Italy. zanib@numerica.it

Telephone: +39-30-3515553 Fax: +39-30-35152224

**Received:** February 24, 2013 **Revised:** March 28, 2013

**Accepted: April 27, 2013**

**Published online:**

**Abstract**

Colorectal cancer is a very common malignancy worldwide and development of liver metastases, both synchronous or metachronous, is a common event. Of all patients with metastatic colorectal cancer, up to 77% have a liver-only disease and approximately 10%-20% of patients with colorectal liver metastases are considered resectable at the time of diagnosis. Surgical resection of liver metastases remains the best treatment option and it is associated with a survival plateau and a 20%-25% of long-term survivors. Perioperative chemotherapy for resectable liver metastases may improve resecability of liver metastases and disease free survival, but its impact on overall survival is still unclear and more studies are needed. Moreover, preoperative chemotherapy can increase postoperative complications. Further studies are needed to define the role of adjuvant chemotherapy after a R0 resection of liver metastases and to define the criteria for a better selection of patients candidate to hepatectomy. New strategies such as targeted therapies are emerging with promising results. Optimal management requires a multidisciplinary approach, local and systemic, but it is a still pending question. Colorectal liver metastases represent a major challenge for oncologists and surgeons. In this review will be analyzed available data about assessment and management of the patients with potentially resectable colorectal liver metastases.

© 2013 Baishideng. All rights reserved.

**Key words:** Colorectal cancer; Liver metastases; Perioperative chemotherapy; Surgical resection; Targeted therapies

**Core tip:** Colorectal cancer is a very common malignancy and its incidence is rapidly increasing worldwide. Of all patients with metastatic colorectal cancer, up to 77% have a liver-only disease and about 10-20% of them are considered resectable at the time of diagnosis. Surgery actually still represents the best option of treatment, but new strategies such as perioperative chemotherapy and targeted therapies are emerging with promising results. However, optimal management requires a multidisciplinary approach, both local and systemic. This review aims to critically analyze the management of potentially resectable colorectal liver metastases.

Meriggi F, Bertocchi P, Zaniboni A. Management of potentially resectable colorectal cancer liver metastases

**Available from:**

**DOI:**

**INTRODUCTION**

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality[1]. The liver is the most common site of CRC metastases and nearly 25% of patients with CRC present with synchronous liver metastases at the time of initial diagnosis and 50%-75% of patients within three years after primary colonic surgery at the time of disease recurrence[2-5]. Though most of these patients have a poor prognosis, there is a subset of patients with liver metastases, both synchronous or metachronous, that can benefit from radical surgery and possibly even achieve cure[6]. In fact, from 25% to 50% of patients with surgically resected colorectal liver metastases (CLM) today can survive five or more years after surgery[7-11]. Unfortunately, only a small percentage of patients, estimated at 10%-20%, exhibits with initially resectable liver metastases[12] and up to 2/3 of patients with resected CLM will experience a recurrence in the majority cases just in the same organ[13,14]. In the last two decades, we have observed remarkable advances in the treatment of CLM, both from a medical point of view with the advent of new chemotherapeutic and biologic agents, and with the improvement of surgical techniques and a better definition of the resectability criteria, thus achieving a median overall survival (OS) of about 24 mo. However, up to now, strong scientific evidences about what is the best strategy for the treatment of CLM are still debated. One of the obstacles to be addressed is the difficulty in defining “Who is resectable?”. The indications for resection of CLM changed significantly over the years. In the late eighties, Ekberg defined restrictive criteria for resectability: less than four metastases (uni or bilobar), absence of extrahepatic disease, and resection margin of at least 1 cm. Moreover, Steele suggested resection of liver metastases only from colorectal primary, three or less lesions, R0 resections, absence of comorbidities and extrahepatic disease[5,15]. Starting from the nineties, these criteria were gradually extended, in relation to location and size of tumor, number of lesions, and absence of extrahepatic disease[16]. Currently, the number or size of hepatic nodules in the hands of trained surgeons and in high-volume liver departments, are no longer considered an absolute contraindication to hepatectomy and the remnant healthy liver is > 25%-30%[17]. Preoperative liver magnetic resonance imaging and intraoperative ultrasound offer the optimal assessment of the number, size, and proximity of tumors to key vascular and biliary structures. Moreover, recent guidelines from the National Comprehensive Cancer Network (NCCN) (v3.2013) recommend a staging positron emission tomographyscan for patients with potentially surgically curable metastatic colorectal cancer. Even the simultaneous presence of potentially resectable extrahepatic disease is no longer an absolute contraindication to surgery of liver metastases, particularly if the extrahepatic disease is surgically resectable lung or ovarian metastases. From 1996 to 2009 were identified at least twelve prognostic scoring-systems, in an attempt to predict survival after resection of CLM as a function of the number of risk factors present in the patient's medical history[18]. One of these scoring-systems was tested by Fong *et al*[3] and assessed five risk factors on approximately 1000 patients: presence of metastatic nodes at the time of the surgery of the primary tumor, disease-free interval < 12 mo, >1 metastatic lesion; size > 5 cm and a value of Carcinoembrionyc Antigen (CEA) >200 ng/mL. The 5-year OS ranges from 14% in patients with five risk factors to 60% in those without risk factors[19]. In an attempt to confirm these results, Tomlinson et al have validated the reliability of this "score", recording a 10-year OS of 21% in resected patients with a low score (0-2) and of 10% in those with a high-risk score (3-5)[20]. On the other hand, Nordlinger score included seven risk factors: age ≥ 60 y, extension into the serosa of the primary cancer, lymphatic spread of the primary cancer, interval less than 2 years from primary tumor to metastases, number of metastases ≥ 4, largest size of liver metastasis ≥ 5, definig three risk groups (low, intermediate, high) with different 2- years survival rates[21].Finally, there are increasing clinical evidences that medical perioperative treatment may improve the outcome of these patients[22,23].

**NEOADJUVANT CHEMOTHERAPY**

Surgery remains the treatment of choice for cure or prolonged survival if it is possible to obtain a radical resection (R0) and with the preservation of a residual functioning liver of 25%-30% of the original liver volume. The term “neoadjuvant chemotherapy” is reserved for chemotherapy for resectable and potentially resectable liver metastases prior to surgery. The role of neoadjuvant chemotherapy in the management of potentially resectable CLM is still controversial and debated[24]. In fact, not infrequently, in patients with favorable prognostic factors, "upfront" surgery of liver metastases is the preferred strategy. An argument in favor of the use of preoperative chemotherapy is that this may be a good test in vivo to evaluate the chemosensitivity of the tumor. Tumor progression while on preoperative treatment is almost always associated with a poor prognosis, even if the metastases will be resected[25]. Perioperative treatment of resectable liver metastases is supported by the phase IIIEuropean Organization for Research and Treatment of Cancer (EORTC) 40983 trial (Table 1). This study randomized 364 patients with 1-4 resectable CLM to 6 cycles of preoperative and 6 cycles of postoperative FOLFOX4 (5-fluorouracil-leucovorin-oxaliplatin) compared with surgery alone. The primary endpoint was progression free survival (PFS). If we consider all of the 364 enrolled patients (182 per arm), the gain in PFS at 3 years was 7.3% in the perioperative chemotherapy arm compared with surgery alone, although this difference was not statistically significant (*P* = 0.058). If you take into account only the patients who underwent a surgical resection of CLM, then the increase in favor of the perioperative treatment reaches the statistical significance (difference in PFS between the two arms of 9.2%, *P* = 0.025)[22]. In a recent update of the study after a median follow-up of 8.5 years, the 5-years OS (secondary endpoint) was found of 7 mo longer in the experimental arm (an increase of 3.4%, HR = 0.88; 95%CI: 0.68-1.14, *P* = 0.339), but also in this case not such to reach a statistical significance. Note that in the experimental arm only 2/3 of resected patients has been able to receive the programmed postoperative chemotherapy and that the post-surgery morbidity was more significant (25% *vs* 16%, *P* = 0.04), although reversible, in patients treated with preoperative chemotherapy. Operative mortality was 1% in both treatments group[23]. It remains unresolved the question whether the benefit in PFS observed in this study is mainly due to the perioperative treatment in toto or primarily to adjuvant post-resection treatment, in favor of which there are several studies that confirm effectiveness[26-31]. Two other small phase II trials support the use of a preoperative treatment with FOLFOX/XELOX (Capecitabine plus Oxaliplatin) and XELOX with bevacizumab[32,33], but before we could say a definitive word on the best approach to the treatment of potentially resectable CLM we still need further dedicated studies, with or without new biological agents. Another aspect to consider in these challenging economic times is cost-effectivness: according to literature, the use of neo-adjuvant chemotherapy could be convenient because it could possibly avoid hepatic resection in those patients who do not respond to this treatment. Nevertheless this analysis is controversial for synchronous resectable metastases[34,35].Neoadjuvant chemotherapy can induce damage to the remnant liver and the risk of hepatic toxicity and surgical complications increase with the duration of pre-opertative treatment[36,37]. Steatosis has been associated with both fluoropyrimidines and irinotecan. Vauthey *et al*[38]reported 20% patients receiving irinotecan having steatohepatitis and this was associated with increased 90-d mortality and morbidity after hepatectomy. Hepatic sinusoidal obstruction syndrome can emerge in patients treated with oxaliplatin but does not seem to be strongly associated with increased postoperative mortality[37,39]. A recent retrospective study evaluated histological specimens from 366 resected patients for CLM after preoperative chemotherapy and found that the two independent prognostic factors for OS after hepatectomy were the overall pathologic response > 75% and, surprisingly, fibrosis > 40% and not necrosis as expected[40]. Another problem with preoperative chemotherapy includes the shrinkage of viable disease, known as “vanishing metastases”, so it is not visible and therefore not resected at laparotomy. However, in many cases, this clinical complete response does not match with pathologic complete response. According to Adam and collegues, the predictive factors for a complete pathologic response are: age ≤ 60 year, size of metastases ≤ 3 cm, CEA levels at diagnosis ≤ 30 ng/mL, and objective response following chemotherapy. Patients who achieved a complete pathologic response after neoadjuvant chemotherapy had high survival rates (76% at 5 year)[41]. Patients should be carefully monitored during chemotherapy and receive surgery before metastases disappear. Therefore, response to neoadjuvant therapy must be closely monitored and it is recommended to revaluate disease after no more than two mo of treatment[42]. The duration of treatment *in toto* (preoperative and adjuvant) should not exceed 6 mo[43]. In summary, many oncologists feel that perioperative therapy is the best current option of treatment for resectable CLM and the recent European Society for Medical Oncology guidelines define this subset of patients with clearly R0-resectable CLM as “Group 0”. The treatment aims of patients placed in “Group 0” is cure and decrease risk of relapse. Hence, the intensity of neoadjuvant treatment will be “nothing” (upfront surgery) or “moderate” (FOLFOX)[44].

**ADJUVANT THERAPY AFTER RESECTION OF LIVER METASTASES**

Nearly 70% of patients relapse after an hepatic resection for CLM and most of them just in the liver and within the first two years after surgery[13,14,45]. In an attempt to improve the outcome of these patients was thus adopted the rationale of adjuvant therapy. Two randomized phase III studies and a subsequent meta-analysis of data extracted by them, have evaluated the role of the combination of bolus fluorouracil and leucovorin (5-FU/LV) for 6 mo after R0 surgery of CLM versus surgery alone[26,27,28]. The results of these studies, although showing a trend in favor of adjuvant chemotherapy both in PFS and OS, do not provide a strong evidence in favor of postoperative treatment, probably due to their limited statistical power and the use of a chemotherapy regimen that actually does not represent the best combination to be administered in patients considered as metastatic patients. There are two additional meta-analyses that support the use of an adjuvant fluoropyrimidine-based treatment[29,30]. In the study of Ychou *et al*[31], the regimen FOLFIRI, as expected, has failed to show advantage in disease free survival (DFS) compared to 5-FU/LV (Table 2). It was argued, as in the classical adjuvant therapy after surgery of the primary tumor, that an oxaliplatin-based regimen[46] may be more effective, but there are no definitive data and studies with the FOLFOX or XELOX regimens with or without biologic agents, are currently ongoing. Several interesting experiences, but difficult to reproduce on a large scale especially for technical difficulties and specific toxicities (*i.e.,* sclerosing cholangitis), were obtained with the administration of a derivate of fluorouracil (floxuridine, FUDR) plus high-dose dexamethasone in the hepatic artery (HAI), using the rationales of the prevalent arterial vascularization of liver metastases and of lower risk of systemic toxicities despite higher doses of chemotherapy[47-53].

In conclusion, it is common practice to administer a postoperative chemotherapy in patients with resected CLM due to the high-relapse rate expectations and the positive impact on PFS, but unfortunately definitive data in favor of adjuvant therapy after R0 resection of CLM are still lacking. Nevertheless, actually the preferred regimens to be administered in these patients are empirically an oxaliplatin-based regimen.

Hence, it will be crucial to identify subsets of patients at increased risk of relapse and candidate to receive adjuvant treatment.

**TARGETED THERAPIES**

More recently, the introduction of new biological drugs in the available arsenal to the oncologist has improved the results obtained in the treatment of metastatic colorectal cancer. In particular, anti-EGFR monoclonal antibodies cetuximab and panitumumab in patients with K-RAS wild-type[54-60] and anti-VEGF antibody bevacizumab[61-64] have shown a synergistic action when associated to classical chemotherapy regimens with two or three drugs, thus increasing significantly the PFS, the overall response rate and hence also the rate of hepatic resection for CLM if compared with chemotherapy alone, especially when used as “conversion” treatment for unresectable liver metastases. Whether these results reflected in a real OS advantage, it still remains unclear. Unfortunately, data about targeted therapies in the perioperative or neoadjuvant setting of resectable CLM are lacking. Gruenberger et al reported their experience of a phase II study with oxaliplatin, capecitabine and bevacizumab in 56 curable CLM patients. This regimen showed a high response rate (73%) with R0 hepatic resections in 52 out of 56 patients and 5 complete pathologic responses[32]. Actually, phase III studies with anti-EGFR antibody cetuximab and with anti-VEGF antibody bevacizumab are ongoing to better define the role of these biological agents in the treatment of potentially resectable CLM.

**CONCLUSION**

CLM are a common problem, but many patients are able to undergo R0 liver resection, and a significant proportion of those patients may achieve cure or at least obtain prolonged DFS[65]. A multidisciplinary team approach is important for coordinating care of patients with CLM. Surgery is the treatment of choice for resectable CLM and requires that an adequate liver remnant remains after surgery. Perioperative chemotherapy with FOLFOX regimen for six mo according to the results of the EORTC 40983 randomized trial improves the outcome of these patients and it is actually recommended for most patients[66-69]. When it is performed an upfront surgery of CLM, then adjuvant chemotherapy with an oxaliplatin-based regimen is a reasonable option. Based on our experience we suggest close follow up schedule for patients who underwent CLM resection. The role of targeted therapies in neoadjuvant setting of potentially resectable CLM remains to be defined and needed further studies. Finally, where a local approach to CLM is indicated and surgery is contraindicated, the radiofrequency ablation of liver metastases is often considered a good alternative, although generally less effective than surgery in terms of relapse rate and OS[70-76].

**REFERENCES**

1 **Jemal A**, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin* 2009; **59**: 225-249 [PMID: 19474385 DOI: 10.3322/caac.20006]

2 **Bengmark S**, Hafström L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. *Cancer* 1969; **23**: 198-202 [PMID: 5763253]

3 **Fong Y**, Kemeny N, Paty P, Blumgart LH, Cohen AM. Treatment of colorectal cancer: hepatic metastasis. *Semin Surg Oncol* 1996; **12**: 219-252 [PMID: 8829283]

4 **Kemeny N**, Fata F. Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. *J Hepatobiliary Pancreat Surg* 1999; **6**: 39-49 [PMID: 10436236 DOI: 10.1007/s005340050082]

5 **Steele G**, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. *Ann Surg* 1989; **210**: 127-138 [PMID: 2667471 DOI: 10.1097/00000658-198908000-00001]

6 **Manfredi S**, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. *Ann Surg* 2006; **244**: 254-259 [PMID: 16858188 DOI: 10.1097/01.sla.0000217629.94941.cf]

7 **Biasco G**, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, Brandi G. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. *Cancer Treat Rev* 2006; **32**: 214-228 [PMID: 16546323 DOI: 10.1016/j.ctrv.2005.12.011]

8 **Stangl R**, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. *Lancet* 1994; **343**: 1405-1410 [PMID: 7515134 DOI: 10.1016/S0140-6736(94)92529-1]

9 **Robertson DJ**, Stukel TA, Gottlieb DJ, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases: a national experience. *Cancer* 2009; **115**: 752-759 [PMID: 19130462 DOI: 10.1002/cncr.24081]

10 **Cummings LC**, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. *Cancer* 2007; **109**: 718-726 [PMID: 17238180 DOI: 10.1002/cncr.22448]

11 **Rougier P**, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, Faivre J. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. *Br J Surg* 1995; **82**: 1397-1400 [PMID: 7489177 DOI: 10.1002/bjs.1800821034]

12 **Wicherts DA**, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. *Eur J Surg Oncol* 2007; **33 Suppl 2**: S42-S51 [PMID: 17981429 DOI: 10.1016/j.ejso.2007.09.017]

13 **Fong Y**, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. *J Clin Oncol* 1997; **15**: 938-946 [PMID: 9060531]

14 **Petrelli NJ**. Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. *J Clin Oncol* 2008; **26**: 4862-4863 [PMID: 18794535 DOI: 10.1200/JCO.2008.18.5868]

15 **Ekberg H**, Tranberg KG, Andersson R, Lundstedt C, Hägerstrand I, Ranstam J, Bengmark S. Determinants of survival in liver resection for colorectal secondaries. *Br J Surg* 1986; **73**: 727-731 [PMID: 3756436 DOI: 10.1002/bjs.1800730917]

16 **Bismuth H**, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. *Ann Surg* 1996; **224**: 509-20; discussion 520-2 [PMID: 8857855 DOI: 10.1097/00000658-199610000-00009]

17 **Berri RN**, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. *Curr Oncol Rep* 2009; **11**: 200-208 [PMID: 19336012 DOI: 10.1007/s11912-009-0029-z]

18 **Gomez D**, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? *HPB (Oxford)* 2010; **12**: 227-238 [PMID: 20590892]

19 **Fong Y**, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 1999; **230**: 309-18; discussion 318-21 [PMID: 10493478 DOI: 10.1097/00000658-199909000-00004]

20 **Tomlinson JS**, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. *J Clin Oncol* 2007; **25**: 4575-4580 [PMID: 17925551 DOI: 10.1200/JCO.2007.11.0833]

21 **Nordlinger B**, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. *Cancer* 1996; **77**: 1254-1262 [PMID: 8608500]

22 **Nordlinger B**, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet* 2008; **371**: 1007-1016 [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9]

23 **Sorbye H**, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). *Ann Surg* 2012; **255**: 534-539 [PMID: 22314329]

24 **Chua TC**, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. *Ann Surg Oncol* 2010; **17**: 492-501 [PMID: 19856028 DOI: 10.1245/s10434-009-0781-1]

25 **Adam R**, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? *Ann Surg* 2004; **240**: 1052-161; discussion 1052-161; [PMID: 15570210]

26 **Langer B,** Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S, Tu D, Sargeant AM, Fields A. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): Results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. *Proc Amer Soc Clin Oncol* 2002; **21**: 149a

27 **Portier G**, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. *J Clin Oncol* 2006; **24**: 4976-4982 [PMID: 17075115 DOI: 10.1200/JCO.2006.06.8353]

28 **Mitry E**, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. *J Clin Oncol* 2008; **26**: 4906-4911 [PMID: 18794541 DOI: 10.1200/JCO.2008.17.3781]

29 **Parks R**, Gonen M, Kemeny N, Jarnagin W, D'Angelica M, DeMatteo R, Garden OJ, Blumgart LH, Fong Y. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. *J Am Coll Surg* 2007; **204**: 753-61; discussion 761-3 [PMID: 17481478 DOI: 10.1016/j.jamcollsurg.2006.12.036]

30 **Kornprat P**, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D'Angelica M. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. *Ann Surg Oncol* 2007; **14**: 1151-1160 [PMID: 17195913 DOI: 10.1245/s10434-006-9068-y]

31 **Ychou M**, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. *Ann Oncol* 2009; **20**: 1964-1970 [PMID: 19567451 DOI: 10.1093/annonc/mdp236]

32 **Gruenberger B**, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 1830-1835 [PMID: 18398148 DOI: 10.1200/JCO.2007.13.7679]

33 **Gruenberger B**, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. *BMC Cancer* 2008; **8**: 120 [PMID: 18439246 DOI: 10.1186/1471-2407-8-120]

34 **Ercolani G**, Cucchetti A, Cescon M, Peri E, Brandi G, Del Gaudio M, Ravaioli M, Zanello M, Pinna AD. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. *Eur J Cancer* 2011; **47**: 2291-2298 [PMID: 21652204 DOI: 10.1016/j.ejca.2011.05.014]

35 **Abbott DE**, Cantor SB, Hu CY, Aloia TA, You YN, Nguyen S, Chang GJ. Optimizing clinical and economic outcomes of surgical therapy for patients with colorectal cancer and synchronous liver metastases. *J Am Coll Surg* 2012; **215**: 262-270 [PMID: 22560316 DOI: 10.1016/j.jamcollsurg.2012.03.021]

36 **Karoui M**, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. *Ann Surg* 2006; **243**: 1-7 [PMID: 16371728 DOI: 10.1097/01.sla.0000193603.26265.c3]

37 **Aloia T**, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. *J Clin Oncol* 2006; **24**: 4983-4990 [PMID: 17075116 DOI: 10.1200/JCO.2006.05.8156]

38 **Vauthey JN**, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. *J Clin Oncol* 2006; **24**: 2065-2072 [PMID: 16648507 DOI: 10.1200/JCO.2005.05.3074]

39 **Rubbia-Brandt L**, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. *Ann Oncol* 2004; **15**: 460-466 [PMID: 14998849 DOI: 10.1093/annonc/mdh095]

40 **Poultsides GA**, Bao F, Servais EL, Hernandez-Boussard T, DeMatteo RP, Allen PJ, Fong Y, Kemeny NE, Saltz LB, Klimstra DS, Jarnagin WR, Shia J, D'Angelica MI. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. *Ann Surg Oncol* 2012; **19**: 2797-2804 [PMID: 22476753 DOI: 10.1245/s10434-012-2335-1]

41 **Adam R**, Wicherts DA, de Haas RJ, Aloia T, Lévi F, Paule B, Guettier C, Kunstlinger F, Delvart V, Azoulay D, Castaing D. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? *J Clin Oncol* 2008; **26**: 1635-1641 [PMID: 18375892 DOI: 10.1200/JCO.2007.13.7471]

42 **Benoist S**, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. *Ann Surg Oncol* 2009; **16**: 2385-2390 [PMID: 19554377 DOI: 10.1245/s10434-009-0492-7]

43 **Adam R**, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. *Oncologist* 2012; **17**: 1225-1239 [PMID: 22962059 DOI: 10.1634/theoncologist.2012-0121]

44 **Schmoll HJ**, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. *Ann Oncol* 2012; **23**: 2479-2516 [PMID: 23012255 DOI: 10.1093/annonc/mds236]

45 **Nakajima Y**, Nagao M, Ko S, Kanehiro H, Hisanaga M, Aomatsu Y, Ikeda N, Shibaji T, Ogawa S, Nakano H. Clinical predictors of recurrence site after hepatectomy for metastatic colorectal cancer. *Hepatogastroenterology* 2001; **48**: 1680-1684 [PMID: 11813600]

46 **Liu JH**, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. *Int J Colorectal Dis* 2010; **25**: 1243-1249 [PMID: 20574727 DOI: 10.1007/s00384-010-0996-4]

47 **BREEDIS C**, YOUNG G. The blood supply of neoplasms in the liver. *Am J Pathol* 1954; **30**: 969-977 [PMID: 13197542]

48 **Kemeny N**, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull AD, Sullivan D, Stockman J, Blumgart LH, Fong Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. *N Engl J Med* 1999; **341**: 2039-2048 [PMID: 10615075 DOI: 10.1056/NEJM199912303412702]

49 **Kemeny NE**, Gonen M. Hepatic arterial infusion after liver resection. *N Engl J Med* 2005; **352**: 734-735 [PMID: 15716576 DOI: 10.1056/NEJM200502173520723]

50 **Kemeny N**, Jarnagin W, Gonen M, Stockman J, Blumgart L, Sperber D, Hummer A, Fong Y. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. *J Clin Oncol* 2003; **21**: 3303-3309 [PMID: 12947066 DOI: 10.1200/JCO.2003.03.142]

51 **Alberts SR**, Roh MS, Mahoney MR, O'Connell MJ, Nagorney DM, Wagman L, Smyrk TC, Weiland TL, Lai LL, Schwarz RE, Molina R, Dentchev T, Bolton JS. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. *J Clin Oncol* 2010; **28**: 853-858 [PMID: 20048179 DOI: 10.1200/JCO.2009.24.6728]

52 **House MG**, Kemeny NE, Gönen M, Fong Y, Allen PJ, Paty PB, DeMatteo RP, Blumgart LH, Jarnagin WR, D'Angelica MI. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. *Ann Surg* 2011; **254**: 851-856 [PMID: 21975318 DOI: 10.1097/SLA.0b013e31822f4f88]

53 **Ito H**, Are C, Gonen M, D'Angelica M, Dematteo RP, Kemeny NE, Fong Y, Blumgart LH, Jarnagin WR. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. *Ann Surg* 2008; **247**: 994-1002 [PMID: 18520227 DOI: 10.1097/SLA.0b013e31816c405f]

54 **Bokemeyer C**, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009; **27**: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]

55 **Van Cutsem E**, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; **360**: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]

56 **Van Cutsem E**, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011; **29**: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]

57 **Maughan TS**, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 2011; **377**: 2103-2114 [PMID: 21641636 DOI: 10.1016/S0140-6736(11)60613-2]

58 **Folprecht G**, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. *Lancet Oncol* 2010; **11**: 38-47 [PMID: 19942479 DOI: 10.1016/S1470-2045(09)70330-4]

59 **Tveit KM**, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. *J Clin Oncol* 2012; **30**: 1755-1762 [PMID: 22473155 DOI: 10.1200/JCO.2011.38.0915]

60 **Douillard JY**, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010; **28**: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860]

61 **Okines A**, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. *Br J Cancer* 2009; **101**: 1033-1038 [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259]

62 **Wong R**, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. *Ann Oncol* 2011; **22**: 2042-2048 [PMID: 21285134 DOI: 10.1093/annonc/mdq714]

63 **Masi G**, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. *Lancet Oncol* 2010; **11**: 845-852 [PMID: 20702138 DOI: 10.1016/S1470-2045(10)70175-3]

64 **Kishi Y**, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. *Ann Surg Oncol* 2010; **17**: 2870-2876 [PMID: 20567921 DOI: 10.1245/s10434-010-1166-1]

65 **Halfdanarson TR**, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. *Cancer J* 2010; **16**: 125-131 [PMID: 20404609 DOI: 10.1097/PPO.0b013e3181d823c8]

66 **Pinto Marques H**, Barroso E, de Jong MC, Choti MA, Ribeiro V, Nobre AM, Carvalho C, Pawlik TM. Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter? *J Surg Oncol* 2012; **105**: 511-519 [PMID: 22065486 DOI: 10.1002/jso.22133]

67 **Kemeny N**. The management of resectable and unresectable liver metastases from colorectal cancer. *Curr Opin Oncol* 2010; **22**: 364-373 [PMID: 20520544 DOI: 10.1097/CCO.0b013e32833a6c8a]

68 **Zdenkowski N**, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. *Oncologist* 2012; **17**: 201-211 [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300]

69 **Piltch A**, Zhang F, Hayashi J. Culture and characterization of thymic epithelium from autoimmune NZB and NZB/W mice. *Cell Immunol* 1990; **131**: 325-337 [PMID: 2242501 DOI: 10.1016/j.critrevonc.2012.02.007]

70 **Abdalla EK**, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004; **239**: 818-25; discussion 825-7 [PMID: 15166961 DOI: 10.1097/01.sla.0000128305.90650.71]

71 **Gleisner AL**, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. *Arch Surg* 2008; **143**: 1204-1212 [PMID: 19075173 DOI: 10.1001/archsurg.143.12.1204]

72 **Wong SL**, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. *J Clin Oncol* 2010; **28**: 493-508 [PMID: 19841322 DOI: 10.1200/JCO.2009.23.4450]

73 **Gibson TB**. Radiofrequency ablation for patients with colorectal cancer and unresectable liver metastasis. *Clin Colorectal Cancer* 2006; **5**: 318-320 [PMID: 16512988 DOI: 10.1016/S1533-0028(11)70201-8]

74 **Reuter NP**, Woodall CE, Scoggins CR, McMasters KM, Martin RC. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? *J Gastrointest Surg* 2009; **13**: 486-491 [PMID: 18972167 DOI: 10.1007/s11605-008-0727-0]

75 **Hur H**, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, Cho CH, Ko HK, Lee JT, Kim NK. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. *Am J Surg* 2009; **197**: 728-736 [PMID: 18789428 DOI: 10.1016/j.amjsurg.2008.04.013]

76 **Ayez N**, Lalmahomed ZS, van der Pool AE, Vergouwe Y, van Montfort K, de Jonge J, Eggermont AM, Ijzermans JN, Verhoef C. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? *Ann Surg Oncol* 2011; **18**: 2757-2763 [PMID: 21638093 DOI: 10.1245/s10434-011-1819-8]

**P-Reviewers** Kirshtein B, Alessandro C

**S-Editor** Zhai HH **L-Editor E-Editor**

**Table 1 European Organization for Research and Treatment of Cancer 40983 Trial**

 *n*  Treatment HR for 3-yr 5-yr Postoperative

 Progression PFS OS Complications

All pts 364 CHT 0.79 35.4 51.2 -

 Surgery alone  *P* = 0.058 28.1 47.8 (*P* = 0.339) -

Elegible pts 342 CHT 0.77 36.2 52.4 -

 Surgery alone *P* = 0.041 28.1 48.3 (*P* = 0.303) -

Resected pts 329 CHT 0.73 42.4 25%

 Surgery alone *P*= 0.025 33.2 16%

Reproduced from reference Nordlinger *et al*[22] and Sorbye *et al*[23]. Pts: Patients; CHT: Chemotherapy; HR: Hazard ratio; PFS: Progression free survival; OS: overall survival.

**Table 2 Phase III Trials of adjuvant chemotherapy after resection of colorectal liver metastases**

Ref  *n*  CHT Median PFS (mo) Median OS (mo)

Langer *et al*[26] 129 5FU/LV No difference No difference

Portier *et al*[27] 173 5FU/LV 24.4 *vs* 16.6 (*P* = 0.028) 62.1 *vs* 46.4 (*P* = 0.13)

Mitry *et al*[28] 278 5FU/LV 27.9 *vs* 18.8 (*P* = 0.059) 61.1 *vs* 46.9 (*P* = 0.125)

Ychou *et al*[31] 306 FOLFIRI *vs* 5FU/LV 24.7 *vs* 21.6 (*P* = 0.44) No difference

CHT: Chemotherapy; PFS: Progression free survival; OS: Overall survival**;** mos: mo;5FU/LV: 5-fluorouracil/Leucovorin; FOLFIRI: 5FU/LV/Irinotecan.